Stock RVTY REVVITY, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Revvity, Inc.

Equities

RVTY

US7140461093

Advanced Medical Equipment & Technology

Market Closed - Nyse
Other stock markets
 04:00:02 2024-04-26 pm EDT 		5-day change 1st Jan Change
101.5 USD -0.57% Intraday chart for Revvity, Inc. +0.64% -7.14%
Apr. 25 Revvity, Inc. Declares Quarterly Dividend, Payable on August 9, 2024 CI
Apr. 25 Early Check Newborn Screening Study Taps Revvity to Provide Genome Sequencing CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 10,788 16,068 25,374 17,712 13,490 12,539 - -
Enterprise Value (EV) 1 12,670 17,657 29,739 21,652 16,476 14,747 14,349 14,727
P/E ratio 47.6 x 22.1 x 25.2 x 30.6 x 19.7 x 45.4 x 36.9 x 32 x
Yield 0.29% 0.2% 0.14% - 0.26% 0.27% 0.27% 0.27%
Capitalization / Revenue 3.74 x 4.25 x 5 x 3.84 x 4.9 x 4.45 x 4.16 x 3.87 x
EV / Revenue 4.39 x 4.67 x 5.87 x 4.7 x 5.99 x 5.24 x 4.77 x 4.55 x
EV / EBITDA 19.6 x 14 x 16.2 x 15.2 x 19.7 x 17.2 x 15.3 x 14.5 x
EV / FCF 44.1 x 21.7 x 22.7 x 36.4 x 1,664 x 32.5 x 22.1 x 20.6 x
FCF Yield 2.27% 4.61% 4.41% 2.74% 0.06% 3.07% 4.53% 4.84%
Price to Book 3.85 x 4.31 x 3.55 x - 1.73 x 1.57 x 1.51 x 1.46 x
Nbr of stocks (in thousands) 111,101 111,974 126,200 126,316 123,407 123,525 - -
Reference price 2 97.10 143.5 201.1 140.2 109.3 101.5 101.5 101.5
Announcement Date 1/27/20 2/2/21 2/1/22 2/14/23 2/1/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 2,884 3,784 5,070 4,611 2,751 2,815 3,011 3,238
EBITDA 1 645.7 1,257 1,838 1,421 836.5 855.9 939.6 1,013
EBIT 1 596 1,203 1,771 1,381 769.9 788.7 868.3 951
Operating Margin 20.66% 31.8% 34.93% 29.95% 27.98% 28.02% 28.84% 29.37%
Earnings before Tax (EBT) 1 237.1 906.4 1,280 - 183 401 476.6 574.7
Net income 1 227.6 727.9 932.2 579.2 693.1 276.1 338.7 388.5
Net margin 7.89% 19.24% 18.39% 12.56% 25.19% 9.81% 11.25% 12%
EPS 2 2.040 6.490 7.990 4.580 5.550 2.234 2.748 3.173
Free Cash Flow 1 287.1 814.7 1,311 594.2 9.904 453.4 650.4 713.3
FCF margin 9.95% 21.53% 25.86% 12.89% 0.36% 16.11% 21.6% 22.03%
FCF Conversion (EBITDA) 44.47% 64.8% 71.3% 41.83% 1.18% 52.97% 69.22% 70.44%
FCF Conversion (Net income) 126.18% 111.92% 140.63% 102.59% 1.43% 164.21% 192.03% 183.61%
Dividend per Share 2 0.2800 0.2800 0.2800 - 0.2800 0.2762 0.2750 0.2733
Announcement Date 1/27/20 2/2/21 2/1/22 2/14/23 2/1/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 1,167 1,365 1,260 1,230 1,033 1,089 675.1 709.3 670.9 696.1 647.5 699.9 709.6 755.4 692.2
EBITDA 1 375 478.2 427.2 420.4 282.6 311.9 206.4 220.5 202 207.7 179.6 211.7 221.3 244.8 216
EBIT 1 358.9 458.7 409.8 401.9 271.7 297.8 189.2 204.3 184.6 191.8 160.9 193.5 204.3 229.2 179.1
Operating Margin 30.75% 33.62% 32.53% 32.68% 26.31% 27.35% 28.03% 28.8% 27.51% 27.55% 24.85% 27.65% 28.79% 30.35% 25.88%
Earnings before Tax (EBT) 1 - - - - - - 29.44 71.55 50.6 31.38 48.56 76.87 87.56 106.2 81.99
Net income 1 127.7 179.2 177 179.2 85.35 137.7 569.5 35.56 9.497 78.56 41.07 66.01 72.12 96.77 60.88
Net margin 10.95% 13.13% 14.05% 14.57% 8.27% 12.64% 84.36% 5.01% 1.42% 11.29% 6.34% 9.43% 10.16% 12.81% 8.8%
EPS 2 1.110 1.410 1.400 1.420 0.6700 1.090 4.500 0.2800 0.0800 0.6400 0.3350 0.5350 0.5850 0.7850 0.5000
Dividend per Share 2 0.0700 0.0700 0.0700 0.0700 0.0700 - 0.0700 0.0700 - 0.0700 0.0700 0.0700 0.0700 0.0700 0.0700
Announcement Date 11/2/21 2/1/22 5/3/22 8/1/22 11/8/22 2/14/23 5/11/23 8/1/23 10/30/23 2/1/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 1,882 1,589 4,366 3,940 2,986 2,208 1,810 2,188
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 2.915 x 1.264 x 2.375 x 2.773 x 3.57 x 2.58 x 1.926 x 2.161 x
Free Cash Flow 1 287 815 1,311 594 9.9 453 650 713
ROE (net income / shareholders' equity) 16.9% 22.2% 17.2% 13.8% 5.57% 7.41% 7.85% 8.48%
ROA (Net income/ Total Assets) 7.31% 10% 8.11% 6.9% 3.07% 4.66% 5.26% 6.17%
Assets 1 3,115 7,274 11,488 8,392 22,588 5,929 6,436 6,300
Book Value Per Share 2 25.20 33.30 56.60 - 63.10 64.80 67.30 69.60
Cash Flow per Share 2 3.260 7.960 12.10 5.380 0.7300 5.120 5.990 6.850
Capex 1 76.3 77.5 99.9 85.6 81.4 80.2 81.1 86.2
Capex / Sales 2.65% 2.05% 1.97% 1.86% 2.96% 2.85% 2.69% 2.66%
Announcement Date 1/27/20 2/2/21 2/1/22 2/14/23 2/1/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Revvity, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
101.5 USD
Average target price
123.2 USD
Spread / Average Target
+21.40%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

1st Jan change Capi.
REVVITY, INC. Stock Revvity, Inc.
-7.14% 12.54B
THERMO FISHER SCIENTIFIC Stock Thermo Fisher Scientific
+8.07% 219B
DANAHER CORPORATION Stock Danaher Corporation
+6.59% 183B
INTUITIVE SURGICAL, INC. Stock Intuitive Surgical, Inc.
+11.26% 133B
BOSTON SCIENTIFIC CORPORATION Stock Boston Scientific Corporation
+26.57% 108B
EDWARDS LIFESCIENCES CORPORATION Stock Edwards Lifesciences Corporation
+13.35% 52.02B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. Stock Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
-0.62% 48.2B
AGILENT TECHNOLOGIES, INC. Stock Agilent Technologies, Inc.
-0.93% 40.37B
GE HEALTHCARE TECHNOLOGIES INC. Stock GE HealthCare Technologies Inc.
+11.54% 39.35B
RESMED, INC. Stock ResMed, Inc.
+26.76% 32.03B
Other Advanced Medical Equipment & Technology
  1. Stock Market
  2. Equities
  3. RVTY Stock
  4. Financials Revvity, Inc.